Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/btpr.3186 http://scihub22266oqcxt.onion/10.1002/btpr.3186 34148295!ä!34148295 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biotechnol+Prog 2021 ; 37 (5): e3186 Nephropedia Template TP {{tp|p=34148295|t=2021. Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak |pdf=|usr=}}{{34148295}} gab.com Text Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak JO: Biotechnol Prog http://www.kidney.de/pget.php?&tw=1&pmid=34148295 #FOAvip The global pandemic outbreak COVID-19 (SARS-COV-2), has prompted many pharmaceutical companies to develop vaccines and therapeutic biologics for its prevention and treatment. Most of the therapeutic biologics are common human IgG antibodies, which were identified by next-generation sequencing (NGS) with the B cells from the convalescent patients. To fight against pandemic outbreaks like COVID-19, biologics development strategies need to be optimized to speed up the timeline. Since the advent of therapeutic biologics, strategies of transfection and cell line selection have been continuously improved for greater productivity and efficiency. NGS has also been implemented for accelerated cell bank testing. These recent advances enable us to rethink and reshape the chemistry, manufacturing, and controls (CMC) strategy in order to start supplying Good Manufacturing Practices (GMP) materials for clinical trials as soon as possible. We elucidated an accelerated CMC workflow for biologics, including using GMP-compliant pool materials for phase I clinical trials, selecting the final clone with product quality similar to that of phase I materials for late-stage development and commercial production. Twit Text FOAVip Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak ????Biotechnol Prog http://www.kidney.de/pget.php?&tw=1&pmid=34148295 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34148295 #FOAvip English Wikipedia <ref>{{Cite pmid|34148295}}</ref> Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak #MMPMID34148295 Zhang Z; Chen J; Wang J; Gao Q; Ma Z; Xu S; Zhang L; Cai J; Zhou W Biotechnol Prog 2021[Sep]; 37 (5): e3186 PMID34148295show ga The global pandemic outbreak COVID-19 (SARS-COV-2), has prompted many pharmaceutical companies to develop vaccines and therapeutic biologics for its prevention and treatment. Most of the therapeutic biologics are common human IgG antibodies, which were identified by next-generation sequencing (NGS) with the B cells from the convalescent patients. To fight against pandemic outbreaks like COVID-19, biologics development strategies need to be optimized to speed up the timeline. Since the advent of therapeutic biologics, strategies of transfection and cell line selection have been continuously improved for greater productivity and efficiency. NGS has also been implemented for accelerated cell bank testing. These recent advances enable us to rethink and reshape the chemistry, manufacturing, and controls (CMC) strategy in order to start supplying Good Manufacturing Practices (GMP) materials for clinical trials as soon as possible. We elucidated an accelerated CMC workflow for biologics, including using GMP-compliant pool materials for phase I clinical trials, selecting the final clone with product quality similar to that of phase I materials for late-stage development and commercial production. |Animals[MESH] |CHO Cells[MESH] |COVID-19/*immunology[MESH] |Cricetulus[MESH] |Disease Outbreaks[MESH]Reshaping cell line development and CMC strategy for fast responses to(epmc).pdf DeepDyve Pubget Overpricing